Dr. Kevin Scott Scher, MBA, MD

Dr. Scher practices at Cedars-Sinai Tower Hematology and Oncology (Tho) - HOPD in Beverly Hills, California.

Dr. Scher's NPI, 1457591075, was assigned on February 22, 2009. Dr. Scher graduated from New York University School of Medicine in 2007. Dr. Scher holds California license A107890.

Dr. Scher's primary practice is Cedars-Sinai Tower Hematology and Oncology (Tho) - HOPD, at 9090 Wilshire Blvd, Beverly Hills, CA 90211.

Dr. Scher's primary practice is Cedars-Sinai Tower Hematology and Oncology (Tho) - HOPD in Beverly Hills, California. Dr. Scher is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Dr. Scher to 2 more home health agencies and 1 group practice or clinic, each named with a free account. Dr. Scher's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Scher practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Scher's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Scher is board certified in hematology by the American Board of Internal Medicine. Dr. Scher is licensed in California.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Scher treats.

CMS data shows 3,719 Medicare services from Dr. Scher across 18 procedure codes in 2024, for 706 Medicare patients. Medicare paid $315,210 for them.

CMS counts 706 Medicare patients who saw Dr. Scher in 2024. The largest group is 75 to 84, with 297 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 19% are also on Medicaid. Their average risk score is 1.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Scher's median patient age at 74, with 43% women.

In 2024, Dr. Scher wrote 1,806 Medicare Part D claims for 302 patients. 65% of them were for generic drugs. CMS names the drug for 1,476 of them, across 36 drugs with 11 or more claims each, at $5,264,902 in total drug cost. In 2023, CMS named 1,038 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Scher for performance year 2024, reported as part of a group. Dr. Scher accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Scher as offering telehealth.

Dmand AI links 17 papers to Dr. Scher, published from 2010 to 2025. 2019 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents and Medical Oncology. Dr. Scher has published most often in J Clin Oncol. Dr. Scher's most frequent co-authors are Allen Szu-Hao Ho, MD, Diana Lu, MD and Idoroenyi Amanam, MD.

Dmand AI links Dr. Scher to 3 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Pancreatic Neoplasms, Stomach Neoplasms and Urinary Bladder Neoplasms.

CMS Open Payments shows 60 general payments to Dr. Scher from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 75% of the total. Bristol-Myers Squibb Company paid the most, $444.

Dr. Scher graduated from New York University School of Medicine in 2007.

Dr. Scher is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.